Russ Conroy

Data from the phase 1/2 EVICTION study support the breakthrough therapy designation for ICT01 plus venetoclax/azacitidine in acute myeloid leukemia.

Osimertinib plus chemotherapy improved overall survival across various subgroups in the phase 3 FLAURA2 trial, including those with CNS metastases.

Data from the phase 3 HARMONi trial support the application for the ivonescimab regimen in this EGFR-mutated NSCLC population.

The FDA no longer considers the phase 3 ALLELE trial adequate to support the approval of tabelecleucel for patients with EBV-positive PTLD.

The safety profile of atezolizumab plus bevacizumab and chemotherapy in this phase 3 trial was comparable with prior reports of the agents.

Data from a phase 1/2a trial show no dose-limiting toxicities associated with ELC-100 among patients with neuroendocrine tumors.

Early data from the ABC-HCC trial showed an improvement in median time to failure of strategy with atezolizumab/bevacizumab vs TACE in this HCC population.

Supporting data for zoldonrasib’s breakthrough therapy designation in NSCLC came from the phase 1 RMC-9805-001 trial.

Investigators will assess the safety and early activity of OTP-01 among patients in the US and Australia across approximately 20 centers.

Data from the CRITICS-II trial support total neoadjuvant chemotherapy plus chemoradiotherapy as a preferred candidate for future study in this population.

Neoadjuvant immunotherapy plus chemotherapy did not definitively increase the risk of severe pneumonitis compared with adjuvant immunotherapy.

Clearance of the investigational new drug application allows investigators to expand their assessment of KLN-1010 as part of the phase 1 inMMyCAR trial.

Prior data from the 2025 ASH meeting showed that CK0804 may complement JAK inhibition among patients with myelofibrosis.

The randomized KANDLELIT-007 trial will enroll approximately 675 patients with advanced non–small cell lung cancer across the world.

Investigators are currently assessing treatment with Alpha DaRT among those with recurrent CSCC as part of the ReSTART trial.

Developers intend to submit a supplemental biologics license application for tafasitamab plus lenalidomide and R-CHOP in this DLBCL population.

Data from the IZALCO trial support the use of subcutaneous on-body injector administration of an isatuximab-based regimen in relapsed/refractory multiple myeloma.

Overall survival significantly improved with radiation plus cisplatin/paclitaxel in the phase 2 RTOG 9911 trial over a historical control cohort.

Sorafenib improved the median progression-free survival compared with placebo among patients with metastatic uveal melanoma in the STREAM study.

Patients currently enrolled on the RAMP 203 trial will have the option of continuing treatment with the avutometinib regimen per investigator discretion.

Data from a phase 2 study may support a novel mTOR inhibitor-based regimen in previously treated, HR-positive, HER2-negative breast cancer.

Data from the phase 3b ALIDHE study may enrich knowledge on ivosidenib plus azacitidine’s safety and efficacy in IDH1-mutated acute myeloid leukemia.

Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.

Treatment with PT-112 appeared to be well-tolerated among those with recurrent thymoma in a phase 2 trial.

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.

Data from the phase 1/2 GO29781 study support the approval of subcutaneous mosunetuzumab in this follicular lymphoma population.

Data from the phase 3 PHILA study support pyrotinib plus trastuzumab as a therapeutic strategy in HER2-positive metastatic breast cancer.

Data from a phase 1 trial may support additional clinical studies of CT0596 in relapsed/refractory multiple myeloma.

Sessions from SABCS 2025 detailed potential advances across different immunotherapy, radiation, and surgical modalities in breast cancer care.